Physician profile
Robert A Franklin
NPI 1942695036
$1,009.25
in general payments reported to CMS, 2019-2025
13 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.95 · 2022: $182 · 2024: $457 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721 · Education: $28.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.44 |
| Education | $28.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $271.53 | 2024-2025 | Lynparza |
| Sobi, INC | $221.31 | 2024 | |
| Aveo Pharmaceuticals, INC. | $99.95 | 2022 | |
| Tempus Ai, INC | $98.42 | 2024 | |
| Incyte Corporation | $81.99 | 2022 | |
| Seagen INC. | $76.95 | 2020 | |
| Ge Healthcare | $51.66 | 2025 | |
| Progenics Pharmaceuticals, INC. | $29.60 | 2025 | |
| Taiho Oncology, INC. | $23.63 | 2025 | |
| Gilead Sciences, INC. | $21.99 | 2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 2025 | Opdivo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.